Diagnostic Value of Metagenomic Next-Generation Sequencing in Refractory Osteomyelitis: A Retrospective Study
This retrospective study demonstrates that metagenomic next-generation sequencing (mNGS) significantly outperforms conventional culture in detecting pathogens and polymicrobial infections, offers faster turnaround times, and more effectively guides antimicrobial therapy for patients with refractory osteomyelitis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Bone infections are a stubborn problem for doctors and patients alike. When bacteria invade bone tissue, the body's natural defenses often struggle to reach the site because blood flow is poor and the bacteria can hide in protective layers. In some cases, the infection refuses to go away despite standard surgery and long courses of antibiotics. This condition is known as refractory osteomyelitis, a term describing infections that persist or return repeatedly. The traditional way to fight these infections relies on growing the bacteria in a laboratory dish, a process called culture. However, this method has a significant flaw: it only finds the microbes that are alive and willing to grow in a dish. If a patient has already taken antibiotics, or if the bacteria are slow-growing or rare, the lab dish often comes up empty, leaving doctors to guess which medicine to use next.
A newer technology called metagenomic next-generation sequencing, or mNGS, offers a different approach. Instead of waiting for bacteria to grow, this method reads the genetic material directly from a sample of infected tissue. It can identify the DNA of bacteria, fungi, and viruses without needing them to be alive or active. While this technology has been used in other areas of medicine, its specific value for the most difficult bone infections has not been fully understood. Researchers wanted to know if this genetic reading tool could find the hidden causes of stubborn infections better than the old lab dishes, and if finding those causes faster would actually change how doctors treat their patients.
To answer these questions, a team of doctors and scientists at Shanghai Sixth People's Hospital and other institutions in China looked back at medical records from 150 patients who had undergone surgery for bone infections between 2021 and 2023. They divided these patients into two groups: those with typical infections that were controlled after one surgery, and those with refractory infections that had required multiple surgeries and continued to cause trouble. For every patient, the team took samples of deep tissue or pus during the operation and sent them for two parallel tests: the standard culture method and the new genetic sequencing method. They then compared what each test found, how long it took to get the results, and whether the new test led to changes in the patients' medication.
The results showed a clear difference in what the two methods could see. The genetic sequencing tool found the cause of the infection in far more patients than the traditional culture method did. In the group with stubborn, recurring infections, the genetic test identified the microbes in 83.3 percent of cases, while the culture method only found them in 28.6 percent. The gap was even wider for patients with typical infections, where the genetic test succeeded in 56.5 percent of cases compared to just 16.7 percent for the culture. The researchers also discovered that stubborn infections were often caused by a mix of different microbes living together, a situation known as polymicrobial infection. The genetic test was much better at spotting these mixed communities, identifying them in 92.31 percent of the difficult cases, whereas the culture method missed them in most instances, finding them in only 11.54 percent.
Speed was another major advantage for the genetic method. While the traditional culture process took an average of 68.2 hours to produce a result, the genetic sequencing provided answers in just 35.0 hours. This nearly halved the time doctors had to wait before knowing which bacteria were present. Because the genetic test found more types of bacteria and identified mixed infections more often, it had a direct impact on treatment decisions. In the group with stubborn infections, the new test results led doctors to change the antibiotic regimen in 61.9 percent of cases. For the group with typical infections, the results prompted a change in 37.0 percent of cases. This suggests that the genetic test provided information that was not only faster but also more complete, allowing for more precise targeting of the infection.
The study concluded that while traditional culture remains a necessary tool for checking how bacteria respond to specific drugs, the genetic sequencing method is a powerful addition for diagnosing difficult bone infections. It excels at finding the complex mix of microbes that often hide in stubborn cases and does so quickly enough to guide immediate treatment. The researchers noted that this approach is particularly valuable for patients who have failed standard treatments or whose lab cultures came back negative. However, they also emphasized that this is a retrospective study, meaning it looked at past data rather than tracking new patients forward in time. They suggested that future studies are needed to confirm that using this technology leads to better long-term health outcomes for patients, but the current findings strongly support its use as a valuable partner to traditional methods in managing the most challenging bone infections.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.